Skip to main content

Market Overview

The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Share:
The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 8)

  • AstraZeneca plc (ADR) (NYSE: AZN)
  • Bio-Rad Laboratories, Inc. (NYSE: BIO)(reported forecasting-beating results for Q2)
  • Endo International PLC (NASDAQ: ENDP)(reacted to a beat-and-raise quarter)
  • Inspire Medical Systems Inc (NYSE: INSP)(reported a narrower-than-expected Q2 loss and forecast 50-54 percent revenue growth for FY18)
  • Horizon Pharma PLC (NASDAQ: HZNP)(reacted to quarterly results)
  • Inogen Inc (NASDAQ: INGN)(reported above-consensus EPS for Q2 and raised its FY18 guidance)
  • Medtronic PLC (NYSE: MDT)
  • OptimizeRx Corporation (NASDAQ: OPRX)(reacted to Q2 results)
  • Pfizer Inc. (NYSE: PFE)
  • SurModics, Inc. (NASDAQ: SRDX)

Zoetis Inc (NYSE: ZTS)

Down In The Dumps

(Biotech Stocks Hitting 52-week lows on Aug. 8)

  • Aileron Therapeutics Inc (NASDAQ: ALRN)(reported a wider-than-expected Q2 loss)
  • Cesca Therapeutics Inc (NASDAQ: KOOL)
  • Citius Pharmaceuticals Inc (NASDAQ: CTXR)
  • Clovis Oncology Inc (NASDAQ: CLVS)
  • CTI BioPharma Corp (NASDAQ: CTIC)
  • Cytori Therapeutics Inc (NASDAQ: CYTX)
  • Enzo Biochem, Inc. (NYSE: ENZ)
  • Flex Pharma Inc (NASDAQ: FLKS)
  • OHR Pharmaceutical Inc (NASDAQ: OHRP)
  • Pain Therapeutics, Inc. (NASDAQ: PTIE)
  • Provention Bio Inc (NASDAQ: PRVB)
  • Pulmatrix Inc (NASDAQ: PULM)
  • Reshape Lifesciences Inc (NASDAQ: RSLS)
  • Sonoma Pharmaceuticals Inc (NASDAQ: SNOA)
  • Synlogic Inc (NASDAQ: SYBX)
  • Titan Medical Inc. (NASDAQ: TMDI)(announced pricing of offering)

Stocks In Focus

Ampio, Regenxbio Slip On News of Common Stock Offering

Ampio Pharmaceuticals Inc (NYSE: AMPE) announced its intention to offer shares and accompanying warrants to purchase shares of common stock in an underwritten public offering. The stock plunged 26.08 percent to $0.45 in after-hours trading.

Regenxbio Inc (NASDAQ: RGNX) said it intends to offer $175 million worth of its common stock in an underwritten public offering. The stock declined 3.68 percent to $68 in after-hours session.

Sangamo Blood Disorder Drug Trial Produces Positive Results

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced positive preliminary data from the Phase 1/2 trial that evaluates its SB-525, a cDNA gene therapy candidate for Hemophilia A. The candidate has been developed under a collaboration between Sangamo and Pfizer Inc. (NYSE: PFE).

"In the Alta study, SB-525 has been generally well tolerated to date with no treatment-related serious adverse events and no use of tapering courses of oral steroids," Sangamo said.

Separately, the company reported a wider-than-expected loss for its Q2.

The stock rose 3.57 percent to $14.345 in after-hours trading.

Related Link: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Stocks Reacting To Earnings

Teligent Inc (NASDAQ: TLGT) said Q2 revenues fell 9 percent year-over-year to $16.8 million. The loss per share also came in wider than expectations. The stock slumped 11.84 percent to $3.50 in after-hours trading.

Insys Therapeutics Inc (NASDAQ: INSY) reported a decline in revenues from $42.6 million in Q2'17 to $23.5 million in Q2, dragged by lower gross revenue and returns of expired product. The loss per share widened from 11 cents to 37 cents. The stock fell 6.01 percent to $7.35 in after-hours trading.

Akebia Therapeutics Inc (NASDAQ: AKBA) said its Q2 loss per share widened from 53 cents to 60 cents, while analysts estimated a narrower loss of 51 cents per share. Collaboration revenues rose from $28.52 million to $48.79 million. The stock plunged 12.55 percent to $8.50 in after-hours trading.

Rigel Pharmaceuticals, Inc (NASDAQ: RIGL) reported a Q2 loss of 16 cents per share, flat with last year and also in line with estimates. The company reported revenues of $1.79 million. The stock rallied 7.81 percent to $2.90 in after-hours trading.

TRACON Pharmaceuticals Inc (NASDAQ: TCON) reported a wider loss of 33 cents per share for Q2, while analysts estimated a loss of 31 cents per share. The stock rallied 19.59 percent to $2.90 in after-hours trading.

On The Radar

Earnings

Before the Market Open

  • Aldeyra Therapeutics Inc (NASDAQ: ALDX) Q2 EPS $(0.46) Misses $(0.43) Estimate
  • Loxo Oncology Inc (NASDAQ: LOXO) Q2 Adj. EPS $(1.68) Misses $(0.54) Estimate, Sales $42.601M Beat $28.91M Estimate
  • Amneal Pharmaceuticals Inc (NYSE: AMRX) Q2 EPS $0.24 Beats $0.22 Estimate, Sales $413.787M Miss $460.81M Estimate
  • Catabasis Pharmaceuticals Inc (NASDAQ: CATB) Q2 EPS $(0.20) Beats $(0.23) Estimate
  • Jounce Therapeutics Inc (NASDAQ: JNCE) Q2 EPS $(0.14) Beats $(0.37) Estimate, Sales $19.378M Beat $12.91M Estimate
  • Pieris Pharmaceuticals Inc (NASDAQ: PIRS) Q2 Sales $11.691M Miss $12.71M Estimate, EPS $0.00 vs $(0.01) Est.
  • BioLife Solutions Inc (NASDAQ: BLFS) Q2 EPS $0.05 Beats $0.04 Estimate, Sales $5.178M Beat $5.15M Estimate
  • Fibrocell Science Inc (NASDAQ: FCSC) Q2 EPS $(1.03) Misses $(0.42) Estimate
  • Portola Pharmaceuticals Inc (NASDAQ: PTLA) Q2 EPS $(1.61) Misses $(1.49) Estimate, Sales $4.011M Miss $6.35M Estimate

After the Market Close

  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
  • Puma Biotechnology Inc (NASDAQ: PBYI)
  • Kindred Biosciences Inc (NASDAQ: KIN)
  • CareDx Inc (NASDAQ: CDNA)
  • Interpace Diagnostics Group Inc (NASDAQ: IDXG)
  • Dova Pharmaceuticals Inc (NASDAQ: DOVA)
  • Endologix, Inc. (NASDAQ: ELGX)
  • Pernix Therapeutics Holdings Inc (NASDAQ: PTX)
  • Organovo Holdings Inc (NASDAQ: ONVO)
  • ICU Medical, Incorporated (NASDAQ: ICUI)
  • Caladrius Biosciences Inc (NASDAQ: CLBS)
  • CymaBay Therapeutics Inc (NASDAQ: CBAY)
  • Zosano Pharma Corp (NASDAQ: ZSAN)
  • KemPharm Inc (NASDAQ: KMPH)
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
  • Viking Therapeutics Inc (NASDAQ: VKTX)
 

Related Articles (IBB + RIGL)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Offerings Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com